Health Canada Issues NOC To Winston Civanex
In a trial, Civanex showed reduction in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain scale, the WOMAC Physical Function Subscale and a Patient Global Evaluation
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).